Manoli Vourvahis - Concepedia

Author

Manoli Vourvahis

Pfizer (United States)ORCID

Also Known As

Cohen, Myron S, M Vourvahis, M. Vourvahis, Manoli Vourvahis, Patterson, K. B.

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Pfizer (United Kingdom)ViiV Healthcare (United Kingdom)Pfizer (Belgium)University of Liverpool

About

Manoli Vourvahis is an author at Pfizer (United States) specializing in pharmacology, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	286
2	Engineering	2	2	55
3	Health Sciences	2	2	27
4	Natural Sciences	1	1	21
5	Allergy	1	1	17

Manoli Vourvahis

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Maraviroc: Pharmacokinetics and drug Interactions David Back, Manoli Vourvahis Antiviral Therapy Drug InteractionsMaraviroc ExposurePharmacological StudyH. MaravirocPharmacology	2009	117
Dose‐Dependent Inhibition of OATP1B by Rifampicin in Healthy Volunteers: Comprehensive Evaluation of Candidate Biomarkers and OATP1B Probe Drugs Daiki Mori, Emi Kimoto, Brian Rago, Clinical Pharmacology & Therapeutics	2019	101
The Pharmacokinetics of Silymarin Is Altered in Patients with Hepatitis C Virus and Nonalcoholic Fatty Liver Disease and Correlates with Plasma Caspase-3/7 Activity Sarah J. Schrieber, Zhiming Wen, Manoli Vourvahis, Drug Metabolism and Disposition	2008	80
A Phenotype–Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir Julie B. Dumond, Manoli Vourvahis, Nardin Rezk, Clinical Pharmacology & Therapeutics	2010	62
Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment John D. Davis, Caroline E. Ridgway, Julia Hamlin, Antiviral Therapy	2008	59
Genital Tract, Cord Blood, and Amniotic Fluid Exposures of Seven Antiretroviral Drugs during and after Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women Rosa F. Yeh, Naser L. Rezk, Angela D. M. Kashuba, Antimicrobial Agents and Chemotherapy Genital TractGynecologyPharmacotherapyAntiviral DrugHigh-risk Pregnancy	2009	57
Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study Neeta B. Amin, Amanda Darekar, Quentin M. Anstee, BMJ Open	2022	50
The Pharmacokinetics and Viral Activity of Tenofovir in the Male Genital Tract Manoli Vourvahis, Hiba L. Tappouni, Kristine B. Patterson, JAIDS Journal of Acquired Immune Deficiency Syndromes	2008	47
Identification of Appropriate Endogenous Biomarker for Risk Assessment of Multidrug and Toxin Extrusion Protein‐Mediated Drug‐Drug Interactions in Healthy Volunteers Takeshi Miyake, Emi Kimoto, Lina Luo, Clinical Pharmacology & Therapeutics	2020	45
Biomarker‐Informed Model‐Based Risk Assessment of Organic Anion Transporting Polypeptide 1B Mediated Drug‐Drug Interactions Emi Kimoto, Chester Costales, Mark A. West, Clinical Pharmacology & Therapeutics	2021	42

Page 1